newsfilter
← Latest News
Business Wire·

ImmunoCellular Therapeutics Appoints John S. Yu, MD, as Interim Chief Executive Officer

LOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) announced today that the Board of Directors has appointed John S. Yu, MD, as Interim Chief Executive Officer and President, and has accepted the resignation of Manish Singh, PhD, effective immediately, from the CEO, President, and Board positions. Dr. Yu will continue to serve as Chief Scientific Officer and Chairman of the Board. ImmunoCellular has initiated a search for a permanent chief executive officer.